Advanced clear cell (cc) renal cell carcinoma (RCC) is a highly vascularized tumor type, which is largely chemoresistant1,2 and therefore commonly treated with antiangiogenic compounds, including tyrosine kinase inhibitors targeted to the vascular endothelial growth factor (VEGF) receptor and anti-VEGF antibodies.3 However, patients with ccRCC who initially respond to VEGF-targeted therapies will usually develop resistance to these agents.4 This evidence concerns the gene VEGFA and renal cell carcinoma.